STUDY QUESTION: What is the cumulative live birth rate following ICSI cycles compared with IVF cycles for couples with non-male factor infertility?
(P < 0.001). Among couples with non-male factor infertility, ICSI resulted in a similar cumulative live birth rate compared with IVF (AHR: 0.96, 95% CI: 0.85-1.10).
Introduction
IVF and ICSI are two techniques used to achieve fertilization in ART. In IVF, sperm are added to each oocyte and in ICSI, a selected spermatozoon is directly injected into each oocyte. Although ICSI was developed for male factor infertility (Palermo, et al., 1992) , there has been an increase in the use of ICSI for all causes of infertility. In Australia, the use of ICSI increased from 57.8% in 2005 to 67.5% in 2014 while the proportion of infertility attributed to male factor was relatively stable over the same period (Harris, et al., 2016; Wang, et al., 2007) . Similar trends have been observed internationally (Nyboe Andersen, et al., 2008) . In the United States, the use of ICSI increased from 36.4% in 1996 to 76.2% in 2012 with the largest relative increase (from 15.4 to 66.9%) occurring in cycles with non-male factor infertility .
Cycle-based studies have found that ICSI is not associated with improved pregnancy or live birth rates compared with IVF regardless of the cause of infertility (Bhattacharya, et al., 2001; van Rumste, et al., 2004; Cissen, et al., 2016; Grimstad, et al., 2016) . A Cochrane review (search date: 2010) of IVF versus ICSI in couples with non-male factor infertility did not report differences in pregnancy rates (van Rumste, et al., 2004) . There were no randomized data comparing live birth rates. The authors concluded that whether ICSI should be preferred to IVF in non-male factor infertility remains an open question (van Rumste, et al., 2004) . A 2016 Cochrane review of ART for male factor infertility found no trials comparing IVF versus ICSI (Cissen, et al., 2016) .
Although outcomes for children born after ICSI compared with IVF are mixed, there are increasing concerns regarding the safety of ICSI. A large Australian study of 1484 babies born following ICSI reported a significantly higher rate of congenital malformations than among 939 babies born following IVF (Davies, et al., 2012) . Other studies have also reported that births resulting from the use of ICSI are associated with increased risks of congenital heart disease (Tararbit, et al., 2013) , autism (Sandin, et al., 2013; and intellectual disability (Sandin, et al., 2013) , and higher rates of admission to a neonatal intensive care unit compared with IVF (Nouri, et al., 2013) . These increased adverse outcomes may be related to the underlying male factor infertility or the ICSI procedure itself which bypasses the natural barriers to fertilization . Nevertheless, some studies have reported no difference or lower risks of adverse birth outcomes in babies born after ICSI compared to IVF (Bonduelle, et al., 2002; Pinborg, et al., 2013; Wen, et al., 2012) .
Cycle-based studies provide limited information for couples who undergo multiple ART cycles, while patient-based studies provide a more accurate estimate of the chance of success with continued treatment (Stern, et al., 2010) . There are currently no patient-based data on the effectiveness of ICSI compared with IVF. There are also limited data on cumulative live birth rates resulting from mostly single embryo transfer (SET) followed by repeated thaw cycles. This study aims to report patient-based outcomes of cumulative live birth rates, including the transfer of fresh and frozen embryos, resulting from a first cycle of ICSI compared with IVF, by cause of infertility.
Materials and Methods

Data source
A population-based cohort of women, who had their first ever stimulated cycle with fertilization performed for at least one oocyte by either IVF or ICSI between July 2009 and June 2014 in the state of Victoria, Australia, was evaluated retrospectively. Treatment characteristics and resulting pregnancy and birth outcome data were obtained from the Victorian Assisted Reproductive Treatment Authority (VARTA), a statutory authority which records details of all initiated ART treatments undertaken in the state. Approximately 30% of all ART treatment cycles reported in Australia are performed in Victoria (VARTA, 2015; Harris, et al., 2016) . Data items in the VARTA dataset are collected on a financial year basis (1 July-30 June) from all fertility clinics in Victoria. The VARTA dataset includes information on demographic characteristics, the type of ART treatment (including conventional-IVF and ICSI), resulting pregnancies (multiple pregnancy, ectopic pregnancy, miscarriage, obstetric complications, etc.) and births outcomes (live birth, gestational age, birthweight, congenital abnormalities, etc.) (VARTA, 2015) .
Study population and follow-up
Between July 2009 and June 2014, 14 693 women had their first ever autologous stimulated cycle with fertilization performed for at least one oocyte by either IVF or ICSI. Data were collated on treatment and clinical outcomes from the first oocyte retrieval (fresh stimulated cycles and associated thaw cycles) performed until June 2016, or until a live birth was achieved, or until all embryos from the first oocyte retrieval had been used. Cycles up to and including the first live birth were included and cycles after the first live birth were excluded. For women with multiple oocyte retrievals during the study period, only cycles from the first oocyte retrieval were included. Only autologous cycles where couples used their own oocytes and sperm were included. Women who had mixed IVF-ICSI cycles (where oocytes from one oocyte retrieval were fertilized by both IVF and ICSI: 3.9%), mixed fresh-frozen cycles (where fresh embryos from subsequent stimulated cycles were added to the frozen embryos from the first stimulated cycles: 1.1%) and preimplantation genetic diagnosis cycles (3.4%) were excluded (Fig. 1) . A total of 4993 women undergoing IVF and 8470 women undergoing ICSI with 8807 and 14 513 initiated cycles (a stimulated cycle with embryos transferred or all embryos cryopreserved for future transfer or a thaw cycle where frozen embryos were thawed with the intention to transfer), respectively, were included in the data analysis.
Follow-up was achieved by using two data items in the VARTA dataset: the patient unique identifier and the statistical linkage key (SLK). The patient unique identifier is assigned by the clinic. The SLK is a combination of the first two letters of a woman's first name, the first two letters of her surname and her date of birth. The combination of the patient unique identifier and the SLK allows the tracking of individual couples' treatments and resulting outcomes within and between clinics.
Study variables and outcome measures
Women were grouped by whether they had undergone IVF or ICSI. The woman's age was calculated in completed years of age at the first stimulated cycle. Cause of infertility was classified as: male factor only infertility (a male factor problem diagnosed and no female factor), female factor only infertility (tubal disease, endometriosis or infertility which the treating clinician believed to be due to 'other female factor' such as fibroids or ovulation disorders and no male factor), combined male-female factor infertility (both male and female factor problems diagnosed), and unexplained infertility (neither a male nor female factor problem diagnosed).
The primary outcome was the cumulative live birth rate. The cumulative live birth rate was defined as live deliveries (at least one live birth) per women after the first stimulated cycles with fertilization performed by Did not achieve live birth and used all embryos from the stimulated cycle n = 4760 (56.2%)
Did not achieve live birth and have remaining embryo(s) from stimulated cycle n = 664 (7.8%)
Achieved live birth n = 1848 (37.0%)
Did not achieve live birth and used all embryos from the stimulated cycle n = 2775 (55.6%)
Did not achieve live birth and have remaining embryo(s) from stimulated cycle n = 370 (7.4%)
Women had first ever autologous stimulated cycle with fertilisation performed for at least one oocyte by either IVF or ICSI n = 14693 Figure 1 Diagram of inclusion and exclusion of the study population. IVF, in vitro fertilisation; ICSI, intracytoplasmic sperm injection; PGD, preimplantation genetic diagnosis.
either IVF or ICSI and associated thaw cycles. A live birth was defined as a baby showing signs of life born at ≥20 weeks gestation or weighing ≥400 g. Multiple births were counted as one live delivery. The observed cumulative live birth rate was reported using the conservative assumption that women who did not return for treatment did not have a pregnancy resulting in a live birth. Fertilization rate was defined as the number of fertilized oocytes obtained per oocytes retrieval or per inseminated oocyte (inseminated for IVF or injected for ICSI).
Statistical methods
Chi-square test, t-test and Mann-Whitney U-test were used to detect differences between the IVF and ICSI groups regarding demographic, clinical and treatment characteristics for categorical and continuous variables. A discrete-time survival model was used to evaluate the prognostic significance of fertilization procedure (IVF versus ICSI) for the cumulative live birth rate (Mills, 2010) . The adjusted hazard ratio (AHR) and 95% CI were calculated. The adjustment was made for year of treatment in which fertilization occurred, the woman's and male partner's age at the first stimulated cycle, parity and the number of oocytes retrieved in the first stimulated cycle. A P-value <0.05 or a CI not including 1 were considered statistically significant. All statistical analysis was performed using SPSS 23.0 software (Armonk, NY, USA: IBM Corp.) and R version 3.4.1 (R Core Team, 2013).
Ethics
Ethics approval for this study was granted by the Human Research Ethics Committee of the University of Technology Sydney, Australia (Reference No. 2015000341) . Access to the VARTA data was granted by VARTA.
Results
The study population included 4993 women undergoing IVF and 8470 women undergoing ICSI, resulting in 7980 and 13 092 embryo transfer cycles with 1848 and 3046 live births, respectively (Fig. 1 ). In the study period, the use of ICSI increased from 52.6% in 2009 to 65.9% in 2014, while the proportion of couples with male factor infertility (male factor only or combined male-female factor) remained relatively stable (26.5% in 2009 and 28.9% in 2014) . Table I presents the demographic and obstetric characteristics of the study population. About one-fifth of the women (19.0% of the IVF group versus 17.9% of the ICSI group) had three or more cycles during the study period. For couples who achieved a live delivery, the median time from oocyte retrieval to live delivery was 8.9 months in both the IVF (range: 4.2-66.5) and ICSI (range: 4.5-71.3) groups (P = 0.474). For couples with a known cause of infertility, male factor infertility was reported for 36.0% in the IVF group and 63.2% in the ICSI group. Non-male factor infertility (female factor only infertility or unexplained infertility) was reported for 64.0% in the IVF group and 36.8% in the ICSI group (P < 0.001).
The fertilization rate per inseminated oocyte was higher in the ICSI group (69.9%) than in the IVF group (59.9%) (P < 0.001), while the fertilization rate per oocyte retrieval was also significantly higher in the IVF group (59.8 versus 56.2%) (P < 0.001). Blastocysts were transferred in 39.8% of cycles in the IVF group, compared with 36.7% in the ICSI group (P < 0.001). The SET rate was 86.2% in the IVF group and 86.0% in the ICSI group (Table II) . The multiple birth rate was 4.3% in the IVF group and 5.1% in the ICSI group (P = 0.22).
The cycle-specific and cumulative live birth rates by fertilization method are shown in Table III . For the first six cycles, the proportion of women who did not return for treatment ranged from 44.3 to 55.3% in the IVF group, compared with 46.1-58.0% in the ICSI group. The cumulative live birth rate was 37.0% in the IVF group and 36.0% in the ICSI group. The cumulative live birth rate did not increase markedly with additional treatments after six cycles.
The cumulative live birth rates by cause of infertility are shown in Table IV and Fig. 2 . The observed conservative cumulative live birth rate was higher for women undergoing IVF cycles compared with ICSI cycles among all causes infertility groups except infertility attributed to male factor only (Fig. 2) . The adjusted overall likelihood of live birth of women undergoing IVF cycles was not significantly different to those undergoing ICSI cycles (AHR: 0.99, 95% CI: 0.92-1.06) (Table IV) . Among couples with non-male factor infertility, ICSI resulted in a (Table IV) .
Discussion
To our knowledge, this is the first population-based cohort study to investigate the cumulative live birth rates following IVF and ICSI. It provides patient-based evidence that ICSI is not associated with an increased likelihood of a live birth, especially for couples with nonmale factor infertility. The routine use of ICSI has been proposed regardless of the cause of infertility with the rationale that ICSI is associated with reduced likelihood of fertilization failure and potentially increased number of embryos (Tucker, et al., 2001; Abu-Hassan and Al-Hasani, 2003) . Our study found that while the fertilization rate per oocyte treated was higher in the ICSI group, the fertilization rate per oocyte retrieved was significantly higher in the IVF group. This may reflect the pre-selection of good quality oocytes for fertilization in the ICSI group in clinical settings. A systematic review and meta-analysis of couples with unexplained infertility favoured the use of ICSI to increase the fertilization rate per retrieved oocyte compared with conventional insemination (pooled relative risk: 1.27, 95% CI: 1.02-1.58) (Johnson, et al., 2013) . The difference between this and the findings in our study is probably attributable to the low IVF fertilization rate (46.7%, n = 930/1988) reported in the five studies included in the meta-analysis which were conducted between 1997 and 2006. Recent studies report comparable or higher fertilization rates per oocyte retrieved for IVF than ICSI (Luna, et al., 2011; Shuai, et al., 2015; Tannus, et al., 2017) . Tannus et al. (2017) found that the IVF group had a higher fertilization rate per oocyte retrieval compared with the ICSI group (57 versus 52%, P = 0.037) in women aged 40 years and over when used for non-male factor infertility. A potential explanation is that the mechanical damage to the oocyte membrane and cytoplasm during the invasive ICSI procedure leads to oocyte degeneration (Ebner, et al., 2001; Rosen, et al., 2006; Tannus, et al., 2017) .
The results of this study demonstrate that ICSI is not associated with increased likelihood of a live birth for non-male factor infertility. This finding is consistent with previous cycle-based studies (Foong, et al., 2006; Grimstad, et al., 2016) and supports the committee opinion of the Practice Committee of the American Society for Reproductive Medicine and Society for Assisted Reproductive Technology that 'there are no data to support the routine use of ICSI for non-male factor infertility' (ASRM, 2012). To date, there is no clinical guideline for the use of ICSI in Australia. In addition, there has been limited information on cost-effectiveness evaluation of ICSI, which is critical to inform public health policy and guide clinical practice. Further cost-effectiveness studies are required to compare the costs associated with treatment and clinical outcomes following IVF and ICSI, and whether these differ by cause of infertility. The findings from our study add significantly to the body of evidence comparing the efficacy of IVF and ICSI procedures in Australian settings, but should be externally validated on data from other countries or clinical settings. ART practice and policy vary significantly between countries. In Australia and New Zealand in 2015, over 80% of embryo transfer cycles were SET cycles and more than two-thirds of autologous fresh cycles where fertilization was attempted used the ICSI procedure (Harris, et al., 2016) . In contrast, the overall proportion of SET was 30.2% in a European register that included 34 countries and ICSI was used in at least 80% of cases in most western and central The denominator is the number of women treated in the cycle cohort. c Including eight live births after the six cycles. Adjusted for year of treatment in which fertilization occurred, woman's and the male partner's age at first stimulated cycle, parity, and number of oocytes retrieved in stimulated cycle. c Including female factor only and unexplained cause of infertility.
European countries (Calhaz-Jorge, et al., 2016) . In addition, the funding model for ART treatment in Australia may differ from those in other countries. Most ART procedures in Australia are subsidized by Medicare, the publicly funded universal health care system (Australian Government Department of Health, 2018).
For couples with male factor only infertility, despite the multivariate analysis being statistically nonsignificant, the observed conservative cumulative live birth rate was higher for women undergoing ICSI (39.9%) compared with IVF (36.2%) and the crude hazard ratio was statistically significant (AHR: 1.21, 95% CI: 1.02-1.44). In our study population, approximately one-fifth of couples with male factor only infertility underwent IVF. It was likely that ICSI was performed based on the severity of male factor infertility where couples who underwent ICSI had more severe male factor infertility than couples who underwent IVF. As the cut off values for semen parameters to decide ICSI may vary across laboratories and clinics (Tournaye, 2012; Cissen, et al., 2016) , it was unclear if the statistically nonsignificant difference in cumulative live birth rate between IVF and ICSI was explained by the underlying male factor infertility (e.g. mild/moderate/severe male factor infertility) or the ICSI treatment itself.
Cumulative live birth rates provide a more accurate estimate of treatment efficacy for couples undergoing multiple cycles than cyclebased rates. Currently, there is no consensus on the preferred method or criteria for presenting the cumulative live birth rate following ART treatment (Maheshwari, et al., 2015; Toftager, et al., 2017) . One critical aspect of examining the cumulative live birth rate is how couples who do not return for ART treatment are addressed in the analysis. A conservative approach assumes that couples do not return for treatment would not have a chance of pregnancy resulting in a live birth, whereas an optimistic approach assumes that couples who do not return have the same chance of a pregnancy resulting in a live birth as couples continuing treatment (Luke, et al., 2012) . The true rate is likely to lie between the conservative and optimistic estimates. To this end, Smith et al. (2015) proposed a prognostic adjusted estimate that adjusted for the proportion of women who do not return due to poor prognosis. Smith et al. assumed that 30% of women discontinued because of poor prognosis and would not have a chance of live birth had they continued. However, it is difficult to evaluate whether the prognostic adjusted estimate based on this assumption would provide a more accurate cumulative live birth rate, since their actual data showed that only 3% of women discontinued due to poor prognosis, as determined by the two strongest prognostic factors: age and the number of oocytes retrieved in the previous cycle (Smith, et al., 2015) . Nevertheless, our study showed a similar proportion of couples who did not return for treatment among women in the IVF and ICSI groups. Parameters that affect the calculation of cumulative live birth rate include the choice of numerator where some studies use the first live birth (Stern, et al., 2010; Luke, et al., 2012) and others use all live births from one oocyte retrieval as the preferred numerator (Li, et al., 2014) . The period of follow-up also plays an important role on computing cumulative live birth rates. Maheshwari et al. (2015) proposed a threestep approach to report short, medium and long-term cumulative live birth rates. The short-term estimate used first live birth from one oocyte retrieval per women in a 2-year period; the medium term estimate used all live birth episodes from one oocyte retrieval within 5 years; and the long-term estimate used all live birth episodes from three oocytes retrievals over 10 years. Our study had a minimum follow-up time of 2 years. Further studies are required to examine the medium and long-term efficacy of IVF compared with ICSI.
A limitation of this population-based study is the lack of information available on clinic-specific protocols and processes for IVF and ICSI and the potential impact of these on clinical outcomes. The management of both female gametes (such as immature oocytes, oocyte degeneration and choice of ICSI timing) and male gametes (such as globozoospermia and DNA fragmentation) may affect the efficacy of ART treatments (Rubino, et al., 2016) . Further studies are required to evaluate the influence of these kinds of technical aspects on clinical outcomes. In addition, the cause of infertility was not available for three main ART providers and the reported causes of infertility were based on the treating clinician's classification which may vary between clinicians. Details of infertility diagnosis and indication for ICSI were not recorded, which may over or underestimate the differences between IVF and ICSI. Furthermore, demographic confounders including BMI and cigarette smoking, medical complications and other residual confounders, which may have affected the findings of this study, are not recorded in the VARTA dataset.
Conclusions
This population-based study found that ICSI resulted in a lower fertilization rate per oocyte retrieved and a similar cumulative live birth rate, compared to IVF. These data suggest that ICSI offers no advantage over IVF in terms of live birth rate for couples with non-male factor infertility.
